From Fig. 2F, it is evident that the primary signaling pathways involved in the treatment of AD by HLJDD include pathways in cancer, lipid and atherosclerosis, neuroactive ligand-receptor interactions, serotonergic synapses, the PI3K-Akt signaling pathway, the Ras signaling pathway, and the MAPK signaling pathway. The gene discussed is AKT1; the disease is cancer.